ClinConnect ClinConnect Logo
Search / Trial NCT04614064

London Underground Study - Health Effects of Particulate Matter

Launched by IMPERIAL COLLEGE LONDON · Oct 28, 2020

Trial Information

Current as of July 21, 2025

Completed

Keywords

Copd Chronic Obstructive Pulmonary Disease Particulate Matter London Underground

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria for both groups:
  • Give informed consent
  • London resident
  • For participants with COPD:
  • GOLD stage 2 COPD (FEV1/FVC\<70%; 50%\>FEV1\<80% predicted), GOLD stage 3 COPD (FEV1/FVC\<70%; 30%\>FEV1\<50%) and GOLD stage 4 (FEV1/FVC\<70%;FEV1\<30%)
  • No history of ischaemic heart disease
  • For healthy volunteers:
  • No history of ischaemic heart disease.
  • Normal lung function with no evidence of airflow obstruction.
  • Exclusion Criteria for both participants with COPD and healthy volunteers:
  • Those with unstable ischaemic heart disease or COPD.
  • Current smokers and those who are ex-smokers of \<12 months duration.
  • Those who work in the London Underground or are occupationally exposed to - - high levels of vehicle traffic exposure on a frequent basis.
  • Those who cannot walk for 30 mins.
  • Involvement in another research study
  • Those unable to give consent.

About Imperial College London

Imperial College London is a world-renowned research institution based in the United Kingdom, recognized for its commitment to advancing medical science and improving patient care through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, Imperial combines expertise across various fields, including medicine, engineering, and business, to drive breakthroughs in healthcare. The institution’s robust clinical trial programs are designed to evaluate new therapies and interventions, ensuring rigorous scientific standards and ethical practices while aiming to translate research findings into tangible benefits for patients and society.

Locations

London, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Frank Kelly

Principal Investigator

Imperial College London

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials